Sectoral Asset Management Inc. Invests $2.47 Million in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Sectoral Asset Management Inc. acquired a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTXFree Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 274,623 shares of the company’s stock, valued at approximately $2,469,000. Sectoral Asset Management Inc. owned 0.37% of Travere Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TVTX. Signaturefd LLC lifted its position in shares of Travere Therapeutics by 1,656.4% during the fourth quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock worth $27,000 after purchasing an additional 2,849 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Travere Therapeutics by 968.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,650 shares of the company’s stock valued at $51,000 after purchasing an additional 5,121 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Travere Therapeutics by 353.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,690 shares of the company’s stock valued at $78,000 after acquiring an additional 6,773 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Travere Therapeutics in the fourth quarter valued at $137,000. Finally, Arizona State Retirement System boosted its holdings in shares of Travere Therapeutics by 9.7% during the 4th quarter. Arizona State Retirement System now owns 20,969 shares of the company’s stock worth $189,000 after buying an additional 1,851 shares during the period.

Analyst Ratings Changes

Several brokerages have recently commented on TVTX. Guggenheim restated a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Wedbush restated an “outperform” rating and set a $13.00 price objective on shares of Travere Therapeutics in a report on Wednesday, April 17th. Wells Fargo & Company raised their price objective on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a report on Friday, February 16th. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $19.00 target price on shares of Travere Therapeutics in a research report on Tuesday, May 7th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.58.

Get Our Latest Stock Analysis on Travere Therapeutics

Travere Therapeutics Trading Down 1.4 %

Travere Therapeutics stock traded down $0.10 during mid-day trading on Friday, reaching $7.13. 625,264 shares of the company traded hands, compared to its average volume of 962,570. The company has a debt-to-equity ratio of 5.10, a current ratio of 2.78 and a quick ratio of 2.75. The firm’s 50 day moving average price is $6.52 and its 200 day moving average price is $7.63. The firm has a market capitalization of $542.81 million, a price-to-earnings ratio of -3.40 and a beta of 0.78. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $17.99.

Travere Therapeutics (NASDAQ:TVTXGet Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). Travere Therapeutics had a negative net margin of 87.94% and a negative return on equity of 238.06%. The company had revenue of $41.40 million for the quarter, compared to analysts’ expectations of $43.46 million. During the same period in the previous year, the firm posted ($1.27) earnings per share. The firm’s revenue for the quarter was up 34.0% compared to the same quarter last year. On average, analysts anticipate that Travere Therapeutics, Inc. will post -3.66 earnings per share for the current fiscal year.

Travere Therapeutics Profile

(Free Report)

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Read More

Institutional Ownership by Quarter for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.